Tacrolimus without or with the addition of conventional immunosuppressive treatment in juvenile autoimmune hepatitis.

Aim: To investigate tacrolimus (Tac)-based treatment in juvenile autoimmune hepatitis (AIH). Twenty patients (13 girls; age, 8-17 years; median, 13.25 years) with AIH were treated with two daily oral doses of Tac.